{"transactions":[{"id":804527,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:15.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000119312526164306/ownership.xml","form_type":"4"}},{"id":804526,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:15.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000119312526164306/ownership.xml","form_type":"4"}},{"id":1440941,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T20:34:23.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":59171},"source":{"system":"sec-edgar","filing":"0000950170-24-090841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017024090841/ownership.xml","form_type":"4"}},{"id":1440940,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T20:34:23.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":367126,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":367126},"source":{"system":"sec-edgar","filing":"0000950170-24-090841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017024090841/ownership.xml","form_type":"4"}},{"id":1440939,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-05T20:34:23.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7527,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 290 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090841","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017024090841/ownership.xml","form_type":"4"}},{"id":1673154,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-23T22:31:30.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":59171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":59171,"derivative":{"underlying":"Common Stock","underlying_shares":59171},"source":{"system":"sec-edgar","filing":"0000950170-24-006666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017024006666/ownership.xml","form_type":"4"}},{"id":1702313,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-22T01:21:14.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":13796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13796},"source":{"system":"sec-edgar","filing":"0000950170-23-072375","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023072375/ownership.xml","form_type":"4"}},{"id":1702312,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-22T01:21:14.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":7072,"price":41.4232,"value":292944.8704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7237,"source":{"system":"sec-edgar","filing":"0000950170-23-072375","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023072375/ownership.xml","form_type":"4"}},{"id":1702311,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-22T01:21:14.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":13796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."}],"balance_after":14309,"source":{"system":"sec-edgar","filing":"0000950170-23-072375","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023072375/ownership.xml","form_type":"4"}},{"id":1719154,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":254262,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":1719153,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-05","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":264262,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":1719152,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-07","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":41.37,"value":413700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."}],"balance_after":513,"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":1719151,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":13.17,"value":131700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."}],"balance_after":10513,"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":1719150,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":35,"value":262500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."}],"balance_after":513,"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":1719149,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-08T00:45:05.000Z","date":"2023-12-05","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":13.17,"value":98775.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 513 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023."}],"balance_after":8013,"source":{"system":"sec-edgar","filing":"0000950170-23-068887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000095017023068887/ownership.xml","form_type":"4"}},{"id":2026624,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-09T01:29:07.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":13796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":13796,"derivative":{"underlying":"Common Stock","underlying_shares":13796},"source":{"system":"sec-edgar","filing":"0000899243-23-004362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924323004362/doc4.xml","form_type":"4"}},{"id":2026623,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T01:29:07.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":54292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":54292,"derivative":{"exercise_price":34.41,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":54292},"source":{"system":"sec-edgar","filing":"0000899243-23-004362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924323004362/doc4.xml","form_type":"4"}},{"id":2191013,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-10T01:18:32.000Z","date":"2022-08-08","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":271762,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-028185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924322028185/doc4.xml","form_type":"4"}},{"id":2191012,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-08-10T01:18:32.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":10000,"price":40.0001,"value":400001.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 - $40.07. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924322028185/doc4.xml","form_type":"4"}},{"id":2191011,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-08-10T01:18:32.000Z","date":"2022-08-08","kind":"exercise","acquired":true,"shares":10000,"price":13.17,"value":131700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-028185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924322028185/doc4.xml","form_type":"4"}},{"id":2401946,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-11T23:43:20.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":58572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter."}],"balance_after":58572,"derivative":{"exercise_price":30.36,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":58572},"source":{"system":"sec-edgar","filing":"0000899243-22-005933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924322005933/doc4.xml","form_type":"4"}},{"id":2683661,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T20:34:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":281762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":281762,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":281762},"source":{"system":"sec-edgar","filing":"0000899243-21-021801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000089924321021801/doc4.xml","form_type":"4"}}]}